Real-world drug survival and reasons for treatment discontinuation of biologics and apremilast in patients with psoriasis in an academic center

Dermatol Ther. 2021 Mar;34(2):e14826. doi: 10.1111/dth.14826. Epub 2021 Feb 12.

Authors

Lawangeen Zeb^{1

2}, Rahul Mhaskar³, Suzanna Lewis¹, Nishit S Patel¹, Divya Sadhwani¹, Nupur Patel¹, Erfon Ekhlassi¹, Yuanyuan Lu³, Lucia Seminario-Vidal¹

Affiliations

¹ Department of Dermatology and Cutaneous Surgery, University of South Florida Morsani College of Medicine, Tampa, Florida, USA.
² Department of Internal Medicine, University of Florida College of Medicine, Gainesville, Florida, USA.
³ Department of Public Health, University of South Florida Morsani College of Medicine, Tampa, Florida, USA.

PMID: 33527682
DOI: 10.1111/dth.14826

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
Biological Products* / adverse effects
Humans
Pharmaceutical Preparations*
Psoriasis* / diagnosis
Psoriasis* / drug therapy
Thalidomide / adverse effects
Thalidomide / analogs & derivatives
Treatment Outcome

Substances

Anti-Inflammatory Agents, Non-Steroidal
Biological Products
Pharmaceutical Preparations
Thalidomide
apremilast

Grants and funding